tetano
Editor, Senior Moderator
Med Microbiol Immunol
. 2022 Jul 2.
doi: 10.1007/s00430-022-00744-7. Online ahead of print.
SARS-CoV-2 herd immunity of the Kyrgyz population in 2021
Anna Y Popova[SUP] 1 [/SUP], Omor T Kasymov[SUP] 2 [/SUP], Vyacheslav Y Smolenski[SUP] 1 [/SUP], Vyacheslav S Smirnov[SUP] 3 [/SUP], Svetlana A Egorova[SUP] 4 [/SUP], Zuridin S Nurmatov[SUP] 2 [/SUP], Anzhelika M Milichkina[SUP] 4 [/SUP], Gulmira S Suranbaeva[SUP] 2 [/SUP], Tatiana E Kuchuk[SUP] 2 [/SUP], Irina V Khamitova[SUP] 4 [/SUP], Elena V Zueva[SUP] 4 [/SUP], Valery A Ivanov[SUP] 4 [/SUP], Zhanylai N Nuridinova[SUP] 2 [/SUP], Aisuluu A Derkenbaeva[SUP] 2 [/SUP], Victoria G Drobyshevskaya[SUP] 4 [/SUP], Gulsun Z Sattarova[SUP] 2 [/SUP], Marat T Kaliev[SUP] 2 [/SUP], Alexandra V Gubanova[SUP] 4 [/SUP], Oyuna B Zhimbaeva[SUP] 4 [/SUP], Alexandra P Razumovskaya[SUP] 4 [/SUP], Vyacheslav N Verbov[SUP] 4 [/SUP], Ivan V Likhachev[SUP] 4 [/SUP], Alexey V Krasnov[SUP] 4 [/SUP], Areg A Totolian[SUP] 4 [/SUP]
Affiliations
Abstract
In the fight against coronavirus infection, control of the immune response is of decisive importance, an important component of which is the seroprevalence of antibodies to SARS-CoV-2. Immunity to SARS-CoV-2 is formed either naturally or artificially through vaccination. The purpose of this study was to assess the seroprevalence of antibodies to SARS-CoV-2 in the population of Kyrgyzstan. A cross-sectional randomized study of seroprevalence was carried out according to a program developed by Rospotrebnadzor and the St. Petersburg Pasteur Institute, taking into account WHO recommendations. The ethics committees of the Association of Preventive Medicine (Kyrgyzstan) and the St. Petersburg Pasteur Institute (Russia) approved the study. Volunteers (9471) were recruited, representing 0.15% (95% CI 0.14-0.15) of the total population, randomized by age and region. Plasma antibodies (Abs) to the nucleocapsid antigen (Nag) were determined. In vaccinated individuals, Abs to the SARS-CoV-2 receptor-binding domain antigen (RBDag) were determined. Differences were considered statistically significant at p < 0.05. The SARS-CoV-2 Nag Ab seroprevalence was 48.7% (95% CI 47.7-49.7), with a maximum in the 60-69 age group [59.2% (95% CI 56.6-61.7)] and a minimum in group 1-17 years old [32.7% (95 CI: 29.4-36.1)]. The highest proportion of seropositive individuals was in the Naryn region [53.3% (95% CI 49.8-56.8)]. The lowest share was in Osh City [38.1% (95% CI 32.6-43.9)]. The maximum SARS-CoV-2 Nag seropositivity was found in the health-care sector [57.1% (95% CI 55.4-58.8)]; the minimum was seen among artists [38.6% (95% CI 26.0-52.4)]. Asymptomatic SARS-CoV-2 Nag seropositivity was 77.1% (95% CI 75.6-78.5). Vaccination with Sputnik V or Sinopharm produced comparable Ab seroprevalence. SARS-CoV-2 Nag seropositivity in the Kyrgyz population was 48.75% (95% CI 47.7-49.7), with the mass vaccination campaign undoubtedly benefitting the overall situation.
Keywords: Antibodies; Kyrgyzstan; N antigen; Population; RBD antigen; SARS-CoV-2; Seroprevalence.
. 2022 Jul 2.
doi: 10.1007/s00430-022-00744-7. Online ahead of print.
SARS-CoV-2 herd immunity of the Kyrgyz population in 2021
Anna Y Popova[SUP] 1 [/SUP], Omor T Kasymov[SUP] 2 [/SUP], Vyacheslav Y Smolenski[SUP] 1 [/SUP], Vyacheslav S Smirnov[SUP] 3 [/SUP], Svetlana A Egorova[SUP] 4 [/SUP], Zuridin S Nurmatov[SUP] 2 [/SUP], Anzhelika M Milichkina[SUP] 4 [/SUP], Gulmira S Suranbaeva[SUP] 2 [/SUP], Tatiana E Kuchuk[SUP] 2 [/SUP], Irina V Khamitova[SUP] 4 [/SUP], Elena V Zueva[SUP] 4 [/SUP], Valery A Ivanov[SUP] 4 [/SUP], Zhanylai N Nuridinova[SUP] 2 [/SUP], Aisuluu A Derkenbaeva[SUP] 2 [/SUP], Victoria G Drobyshevskaya[SUP] 4 [/SUP], Gulsun Z Sattarova[SUP] 2 [/SUP], Marat T Kaliev[SUP] 2 [/SUP], Alexandra V Gubanova[SUP] 4 [/SUP], Oyuna B Zhimbaeva[SUP] 4 [/SUP], Alexandra P Razumovskaya[SUP] 4 [/SUP], Vyacheslav N Verbov[SUP] 4 [/SUP], Ivan V Likhachev[SUP] 4 [/SUP], Alexey V Krasnov[SUP] 4 [/SUP], Areg A Totolian[SUP] 4 [/SUP]
Affiliations
- PMID: 35780233
- DOI: 10.1007/s00430-022-00744-7
Abstract
In the fight against coronavirus infection, control of the immune response is of decisive importance, an important component of which is the seroprevalence of antibodies to SARS-CoV-2. Immunity to SARS-CoV-2 is formed either naturally or artificially through vaccination. The purpose of this study was to assess the seroprevalence of antibodies to SARS-CoV-2 in the population of Kyrgyzstan. A cross-sectional randomized study of seroprevalence was carried out according to a program developed by Rospotrebnadzor and the St. Petersburg Pasteur Institute, taking into account WHO recommendations. The ethics committees of the Association of Preventive Medicine (Kyrgyzstan) and the St. Petersburg Pasteur Institute (Russia) approved the study. Volunteers (9471) were recruited, representing 0.15% (95% CI 0.14-0.15) of the total population, randomized by age and region. Plasma antibodies (Abs) to the nucleocapsid antigen (Nag) were determined. In vaccinated individuals, Abs to the SARS-CoV-2 receptor-binding domain antigen (RBDag) were determined. Differences were considered statistically significant at p < 0.05. The SARS-CoV-2 Nag Ab seroprevalence was 48.7% (95% CI 47.7-49.7), with a maximum in the 60-69 age group [59.2% (95% CI 56.6-61.7)] and a minimum in group 1-17 years old [32.7% (95 CI: 29.4-36.1)]. The highest proportion of seropositive individuals was in the Naryn region [53.3% (95% CI 49.8-56.8)]. The lowest share was in Osh City [38.1% (95% CI 32.6-43.9)]. The maximum SARS-CoV-2 Nag seropositivity was found in the health-care sector [57.1% (95% CI 55.4-58.8)]; the minimum was seen among artists [38.6% (95% CI 26.0-52.4)]. Asymptomatic SARS-CoV-2 Nag seropositivity was 77.1% (95% CI 75.6-78.5). Vaccination with Sputnik V or Sinopharm produced comparable Ab seroprevalence. SARS-CoV-2 Nag seropositivity in the Kyrgyz population was 48.75% (95% CI 47.7-49.7), with the mass vaccination campaign undoubtedly benefitting the overall situation.
Keywords: Antibodies; Kyrgyzstan; N antigen; Population; RBD antigen; SARS-CoV-2; Seroprevalence.